No image available for this title

LITERATURE

Phase I Trial of Docetaxel Administered by Weekly Infusion in Patients With Advanced Refractory Cancer


Docetaxel is a highly active antineoplastic agent; however, grade IV leukopenia occurs in the large majority of patients treated with a dose of 100 mg/m2
every 3 weeks. Recent experience with weekly paclitaxel has demonstrated a bone marrow-sparing effect when a weekly administration schedule is used. We
investigated a weekly schedule of docetaxel in an attempt to alter the toxicity profile and improve the therapeutic index


Availability

Docetaxel-004Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
J Clin Oncol 16:2164-2168
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous